HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is based in Port Moody, Canada.
Metrics to compare | HAVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHAVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −5.2x | −0.7x | |
PEG Ratio | 0.00 | −0.08 | 0.00 | |
Price/Book | 0.0x | −0.6x | 2.6x | |
Price / LTM Sales | 0.0x | 96.3x | 3.4x | |
Upside (Analyst Target) | 0.0% | 173.5% | 38.2% | |
Fair Value Upside | Unlock | −8.4% | 4.6% | Unlock |